Long-Term Changes in Complete Blood Count-Derived Inflammatory Indices During Risankizumab Treatment for Psoriasis: A 208-Week Multicenter Real-World Study.

@article{balestri2026longterm,
  title = {{Long-Term Changes in Complete Blood Count-Derived Inflammatory Indices During Risankizumab Treatment for Psoriasis: A 208-Week Multicenter Real-World Study.}},
  author = {Riccardo Balestri and Chiara Pallanch and Michela Magnano and Jacopo Colombini and Giacomo Clarizio and Federico Bardazzi and Vito Di Lernia and Francesca Satolli and Giulia Ganzetti and Cinzia Buligan and Vanessa Mazzoletti and Lucrezia Pacetti and Giulia Odorici and Alessandro Borghi and Rosita Saraceno and Massimiliano Mengarino and Paolo Gisondi and Giampiero Girolomoni and Rossella Lacava and Giulia Rech and Francesco Bellinato},
  journal = {Antibodies (Basel, Switzerland)},
  year = {2026},
  month = oct,
  doi = {10.3390/antib15050097},
  url = {https://europepmc.org/article/MED/42930039},
  note = {CC BY},
}

TY  - JOUR
TI  - Long-Term Changes in Complete Blood Count-Derived Inflammatory Indices During Risankizumab Treatment for Psoriasis: A 208-Week Multicenter Real-World Study.
AU  - Riccardo Balestri
AU  - Chiara Pallanch
AU  - Michela Magnano
AU  - Jacopo Colombini
AU  - Giacomo Clarizio
AU  - Federico Bardazzi
AU  - Vito Di Lernia
AU  - Francesca Satolli
AU  - Giulia Ganzetti
AU  - Cinzia Buligan
AU  - Vanessa Mazzoletti
AU  - Lucrezia Pacetti
AU  - Giulia Odorici
AU  - Alessandro Borghi
AU  - Rosita Saraceno
AU  - Massimiliano Mengarino
AU  - Paolo Gisondi
AU  - Giampiero Girolomoni
AU  - Rossella Lacava
AU  - Giulia Rech
AU  - Francesco Bellinato
PY  - 2026
DA  - 2026/10/14
JO  - Antibodies (Basel, Switzerland)
DO  - 10.3390/antib15050097
UR  - https://europepmc.org/article/MED/42930039
AB  - Background/Objectives: Blood count-derived inflammatory indices have been proposed as accessible biomarkers of systemic inflammation in psoriasis, but their longitudinal behavior during selective interleukin-23 blockade remains uncertain. We evaluated these indices in psoriasis patients treated with risankizumab. Methods: We conducted a multicenter retrospective real-world study (DERMIS), including adults with cutaneous psoriasis, with or without psoriatic arthritis, treated with risankizumab across 10 Italian centers, from national reimbursement up to 1 December 2025. Psoriasis Area and Severity Index (PASI) and complete blood count-derived indices-neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI)-were assessed at baseline and at weeks 12, 24, 52, 104, 156, and 208. Analyses used available data and sensitivity cohorts with follow-up at weeks 52, 104, and 208. Results: Among 250 patients, 43 had data at week 208. PASI scores decreased significantly at all follow-up time points. In contrast, systemic indices showed heterogeneous, non-linear trajectories: NLR, SII, and SIRI fluctuated without consistent sustained reductions, whereas MLR remained broadly stable. PLR showed the most reproducible downward trend, with nominal reductions at weeks 24 and 52; after Bonferroni correction across the six repeated visits within PLR, the reduction at week 52 remained statistically significant, whereas the week-24 reduction did not. Body mass index (BMI)-related differences were inconsistent and did not remain significant after Bonferroni correction. Sex, cardiometabolic comorbidities, and previous biological exposure showed no consistent effect. Conclusions: These findings challenge the use of routine blood count-derived indices as reliable biomarkers of cutaneous response to risankizumab.
SN  - 2073-4468
ER  -